IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with ...
Scientific Research Publishing

Acute Metabolic and Neurocognitive Adaptations to Short-Term Fasting ()

Bricker, D. , Alberto, J. , Pecar, Z. , Pecar, D. and Asad, S. (2025) Acute Metabolic and Neurocognitive Adaptations to Short-Term Fasting. Food and Nutrition Sciences, 16, 1489-1501. doi: 10.4236/fns ...
Techno-Science.net on MSN

💊 Breast cancer: this new treatment shows very encouraging results

In the ICARUS-BREAST 01 study, more than half of patients with metastatic breast cancer saw their disease decrease or ...